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[1] Thispublication isa compilationof observationsmadeby
physicians in treating their patients of ST Elevation
Myocardial Infarction (STEMI) with the indigenous ten-
ecteplase. It is a registry which is observational,
non-interventional and retrospective in nature. Patient
identity was not revealed. Hence there was no require-
ment for informedconsentor ethics committeeapproval.
[2] Records of patients who received the indigenous ten-
ecteplase only were compiled. Records of other patients
were not compiled or evaluated.
[3] Clinically successful thrombolysis was judged by (a).
Resolution of chest pain & (b) 50% ST segment resolu-
tion at 90 minutes. Pain relief assessment was subjec-
tive and was noted as Yes/No. No pain scale was used.
There was no central ECG monitoring.
The study did not look at the angiographic profile. However
a sub study is being planned to look into the angiographic
patency rates and TIMI flow.
[4] Analysiswas done comparing the overall groupwith the
high risk subgroups, as also between subgroups (elderly
vs nonelderly; diabetics vs nondiabetics; male vs
female) ref. Fig 4 in the article.1
[5] We fully agree with the author’s contention that the
young age of the populationmight have been responsible
for the low mortality figures. However, divergent data
(including time of presentation, delay of thrombolysis)
complicate the issue. In the Fibrinolytic Therapy Trialists
(FTT) collaborative group data,2 the overall 30-day mor-
tality in the age group less than 55 years was 4.6% in the
control group and 3.4% in the thrombolysed group.
The figures quoted by the corresponding author show
substantial relative risk reduction in young STEMI patients
who received reperfusion therapy. Indian patients are
known to get Acute Coronary Syndrome (ACS) at a younger
age than their western counterparts.Randomized Clinical Trials (RCT) is certainly the gold
standard in clinical trials. But observational registry data
reflect real life scenario. The debate of superiority of each is an
open and ongoing academic debate. We need to use the “reg-
istries to investigate the past and develop the future”.3 Well
designed post-marketing surveillance registries can be used to
prove safety and efficacy in a broad spectrum of patients.4
The whole purpose of this registry was to examine the ef-
ficacy and safety of a low cost indigenous tenecteplase in a
financially challenged heterogenous population of India.r e f e r e n c e s
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